Acessa is a company.
Acessa Health Inc. was a women's health company that developed and marketed the Acessa ProVu system, a minimally invasive solution for treating uterine fibroids. The company was acquired by Hologic in 2020.
Key people at Acessa.
Acessa was founded by Kim Rodriguez (President, CEO & Co-Founder).
Key people at Acessa.
Acessa Health Inc. is a women's health medtech company that developed the Acessa System, a minimally invasive radiofrequency ablation device for treating symptomatic uterine fibroids while preserving the uterus.[1][2][4] It serves gynecologists and women suffering from fibroids—a condition affecting millions worldwide—solving the problem of debilitating symptoms like heavy bleeding and pain through a laparoscopic ultrasound-guided procedure that avoids hysterectomy.[1][2] The company raised $30.68M in funding, including a $30M Series A, before being acquired by Hologic in 2020 for ~$80M cash plus contingents, accelerating commercial adoption in a market projected to reach $5.26B by 2027.[2][4][5]
Headquartered in Austin, Texas, Acessa employed ~35 people pre-acquisition and focused on expanding clinical data, next-gen tech, and global access to uterine-sparing solutions in a segment lacking innovation.[1][2]
Acessa Health emerged from the invention of its core technology by Dr. Bruce Lee, a board-certified gynecologist who pioneered radiofrequency ablation under laparoscopic ultrasound guidance for fibroids.[1][2] The company acquired the Acessa System assets from Halt Medical Inc. via a purchase agreement, marking its formal launch with a $30M Series A from investors like S3 Ventures, Sands Capital Ventures, and Murray Enterprises.[1][3][4]
Kim Rodriguez (also referenced as Kim Bridges) served as CEO and co-founder, driving the transition to a dedicated entity focused on women's health innovation.[1][3] Dr. Lee joined as senior medical advisor post-acquisition, highlighting early clinical momentum that positioned Acessa for broader impact.[1]
Acessa rides the wave of minimally invasive gynecology, addressing uterine fibroids—affecting up to 80% of women by age 50—with less disruptive alternatives to hysterectomies amid rising demand for fertility-preserving options.[1][2][4] Timing aligned with a booming $5.26B fibroid treatment market (9.4% CAGR to 2027), fueled by aging populations, awareness, and medtech shifts toward outpatient procedures.[4]
Its Hologic integration influences the ecosystem by strengthening GYN portfolios, accelerating physician adoption via established networks, and setting standards for ultrasound-guided ablation in women's health.[2][6]
Post-2020 acquisition, Acessa thrives within Hologic, likely expanding globally with enhanced R&D and sales, capitalizing on fibroid market growth and trends like personalized, outpatient medtech.[2][4] Evolving demographics and tech like AI-guided imaging could amplify its influence, potentially dominating uterine-sparing treatments.
This positions Acessa as a pivotal innovator, transforming fibroid care from its Austin roots into a global standard.[1][2]
Acessa was founded by Kim Rodriguez (President, CEO & Co-Founder).
